USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: DESIGNMEDIX, INC.
Address: 2828 Corbett Ave Suite 140A
PORTLAND, OR 97201-4830
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $102,614.00 1
STTR Phase I $703,876.00 2
STTR Phase II $1,327,608.00 1

Award List:

Designed Antimalarial Agents Overcoming Chloroquine-Resistance

Award Year / Program / Phase: 2007 / STTR / Phase I
Agency: HHS
Research Institution: PORTLAND STATE UNIVERSITY
Principal Investigator: David H. Peyton
Award Amount: $103,876.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): The intent of the work presented in this proposal is to counter the worldwide health problem brought on by the spread of chloroquine-resistant malaria. To address the need for an orally available and inexpensive replace ment drug, we have developed a novel class… More

Designed Antimalarial Agents Overcoming Chloroquine-Resistance

Award Year / Program / Phase: 2009 / STTR / Phase II
Agency: HHS
Research Institution: PORTLAND STATE UNIVERSITY
Principal Investigator: David H. Peyton
Award Amount: $1,327,608.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): DesignMedix has developed a novel class of compounds to address the pressing need for an orally available, inexpensive drug to counter the spread of chloroquine-resistant malaria. Preliminary data showed that this novel class of molecules, called reversed… More

Preclinical development of novel small molecule malaria drugs that overcome drug

Award Year / Program / Phase: 2011 / STTR / Phase I
Agency: HHS
Research Institution: PORTLAND STATE UNIVERSITY
Principal Investigator: David H. Peyton – 503-725-3875
Award Amount: $600,000.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): The worldwide health problem created by malaria has been made more difficult by the spread of drug- resistant parasites. This project initiates preclinical development of one or more candidate(s) from an innovative newclass of potent antimalarials designed to… More

Optimization of a novel antimalarial drug candidate for plant-scale synthesis

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Steven Burgess – 503-484-7026
Award Amount: $102,614.00
Abstract:
DESCRIPTION (provided by applicant): There is a great need for anti-malarial drugs that are inexpensive and effective against drug-resistant strains. Malaria is one of the most important diseases worldwide, with over 225 million cases each year, and about800 thousand deaths. Most of these deaths… More